The efficacy of the HbOC conjugate Haemophilus influenzae type b vaccine was evaluated
in a study population of 61 080 infants in the Northern California Kaiser Permanente Medical …

Between February, 1988, and June, 1990, the safety, immunogenicity and efficacy of the
HbOC (oligosaccharide conjugate Haemophilus influenza type b) vaccine was evaluated in …

A Haemophilus influenzae type b oligosaccharide-CRM197 conjugate (HbOC) vaccine was
evaluated for safety and immunogenicity in 432 infants 1 to 6 months of age. In a multicenter …

In recent months much controversy has focused on interpretations of new data concerning
the safety and efficacy of Haemophilus influenzae type b vaccines. 1-3 These controversies …

Disease caused by H. influenzae type b is a world-wide problem of major proportions that
affects both developed and developing countries. Young children are at particularly high risk …

Late in 1991, before the implementation of a national immunization program against
Haemophilus influenzae type b (Hib) in the United Kingdom, we performed a 4-year follow …

Background. Haemophilus influenzae type b is the leading cause of invasive bacterial
disease in young children. The capsular polysaccharide vaccine does not protect children at …

HAEMOPHILUS INFLUENZAE TYPE B is the leading cause of bacterial meningitis in the
United States'2 with an estimated 10,000 to 15,000 cases per year. In addition, this organism …

Rates of invasive Haemophilus influenzae type b (Hib) disease in children decreased very
rapidly after licensure of Hib conjugate vaccines. A role for a vaccine-related reduction in …

Objective: To compare the immunogenicity of three Haemophilus influenzae type b (HIb)
conjugate vaccines in infants residing in different geographic areas. Design: A multicenter …